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Background: Constrained acetabular devices were developed to prevent dislocations after total hip
arthroplasty (THA). However, the data on their success have been contradictory. In this study, we aimed
to assess implant survival of the constrained acetabular device in primary THA based on the Finnish
Arthroplasty Register data.
Methods: A total of 373 primary THAs with constrained acetabular devices inserted from 2006 to 2017
were included. A reference group was formed on a 1:3 basis and matched for age, sex, and diagnosis,
consisting of 1118 conventional THAs. Implant survival estimates using death as a competing risk were
assessed with revision for any reason and for any aseptic reason as the endpoints. The Cox multiple
regression models were adjusted for age, sex, and diagnosis. The mean follow-up time was 3.3 (0-12.4)
years for the constrained device group and 3.8 (0-12.0) years for the reference group.
Results: Overall, there were 21 revisions in the constrained device group and 49 in the reference group.
The 8-year survivorship for any reason was 94% (conﬁdence interval [CI]: 91-96) for the constrained
device group and 93% (CI: 89-97) for the reference group. With revision for any aseptic reason as the
endpoint, the 8-year survivorships were 97% (CI: 95-99) and 94% (CI: 90-98), respectively. During the
ﬁrst 1.5 years, the constrained acetabular device group had a similar revision risk (hazard ratio: 1.09 [CI:
0.57-2.07], P ¼ .8) to that of the reference group.
Conclusion: The constrained acetabular device had good survival in primary THA, and our results support
its continued use even in high-risk patients.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).he ethical approval was ob-
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Inc. This is an open access article uDislocation is one of the most common reasons for revision
surgery after primary total hip arthroplasty (THA), covering 17%-
21% of all ﬁrst-time revisions [1,2]. The dislocation incidence during
the ﬁrst postoperative year after primary THA varies from 2% to 4%
[3e5]. Both patient-related and surgical factors such as posterior
approach, poor component positioning, small femoral head size,
poor repair of soft tissues, and implant choice may predispose to
THA dislocation [3,4,6e8]. As the outcome after revision THA is
generally poorer than that after primary THA and the complication
rate is higher, it is important to prevent ﬁrst-time dislocations.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Study devices. (A) Freedom constrained liner made of ArCom isostatically molded polyethylene and a titanium constraint ring. (B) Freedom constrained cemented cup.
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THA. Currently, the three main options available that provide some
protection against dislocation are dual mobility implants, large-
diameter femoral heads, and constrained acetabular devices.
Despite some variability in the data on the ability of constrained
acetabular devices to prevent dislocation and restore stability to
prevent recurrent dislocation, they have become a generally
accepted option worldwide for treating instability in revision THA
[9e11]. However, the role of constrained cups in primary THA in
preventing dislocations in high-risk patients has not been settled.
Despite their advantages in terms of stability, constrained devices
may result in a restricted range of motion and have a greater
prevalence of impingement of the femoral neck on the cup.
Impingement is responsible for high stress transmission tomultiple
interfaces, leading to liner damage, locking mechanism failure,
dislocation, and loosening [10]. Therefore, the constrained acetab-
ular device system is intended only for special situations where the
patient has a high risk of dislocation because of a previous history
of dislocation, severe joint laxity, palsy of the surrounding
musculature, or abductor muscle deﬁciency.
The purpose of this study was to assess the revision rate asso-
ciated with the constrained acetabular device in primary THA and
to compare it with a conventional THA reference group with (1)
revision for any reason, (2) revision for dislocation, (3) revision for
any aseptic reason, and (4) revision for infection as the endpoints,
based on data from the Finnish Arthroplasty Register (FAR).
Patients and Methods
This study is based on data from the FAR, which covers most of
the total hip implants performed in Finland since 1980 [12]. Or-
thopedic units are obligated to provide all the information essential
for maintenance of the register to the Finnish National Institute for
Health and Welfare. In Finland, the data completeness for primary
THA is >95%, and for revision THA, 81% [2]. Dates of death areobtained from the Population Information System maintained by
the Population Register Center. Since May 2014, implant identiﬁ-
cation has been performed by electronic scanning of reference
codes in operating theaters, and the operative information is then
sent electronically to the register [2].
Study Device
The Freedom (Zimmer Biomet, Warsaw, IN) constrained
acetabular device system was introduced in Finland in 2006 and is
currently the most commonly used constrained device in the
country. It incorporates an equatorial ﬂat section at 15 to the
vertical axis along the sides of the constrained liner and a modular
chrome-cobalt head which is always 36 mm in diameter (Fig. 1-A).
The components are manufactured in such a way that ﬂuid creates
a suction effect between the head and liner. This constrained
acetabular device provides a 110 range of motion and lever-out
strength of 198 inch-lbs [12]. The acetabular liner can be locked
into a standard locking mechanism for use in primary and revision
acetabular components. A cemented version (Fig. 1-B) is available
for cementing into a well-ﬁxed acetabular shell of differing locking
design or in cases where the locking mechanism is no longer
functioning properly. The cemented version may also be directly
cemented to the pelvic bone without any further complementing
parts.
Study Population
Between January 2006 and December 2017, 373 primary THAs
were performed using either a cemented constrained cup (n¼ 220)
or constrained liner attached to an uncemented cup (n ¼ 153)
(Fig. 1). The uncemented cups used with the liner were Vision
RingLoc (Zimmer Biomet, Warsaw, IN), Regenerex (Zimmer Biomet,
Warsaw, IN), Exceed (Zimmer Biomet, Warsaw, IN), and Trabecular
Metal shell (Zimmer Biomet, Warsaw, IN). The head size used with
Table 1
Demographic Data.
Data Constrained Acetabular Device Reference
Mean age years and SD 71.0, SD: 12.1 70.5, SD: 12.0
Mean follow-up time in years,
minimum-maximum
3.3, 0-12.4 3.8, 0-12.0
Age group
<49 17 (4.5) 51 (4.5)
50-54 15 (4.0) 45 (4.0)
55-59 28 (7.5) 84 (7.5)
60-64 43 (11.5) 129 (11.5)
65-69 61 (16.3) 183 (16.3)
70-74 48 (12.8) 144 (12.8)
75-79 64 (17.1) 192 (17.1)
80þ 98 (26.2) 293 (26.1)
Gender
Male 163 (43.6) 489 (43.6)
Female 211 (56.4) 632 (56.4)
Diagnosis
Primary osteoarthritis 78 (20.9) 234 (20.9)
Rheumatoid arthritis 4 (1.1) 12 (1.1)
Other 292 (78.1) 875 (78.1)
Status
Not revised 352 (94) 1069 (96)
Revised 21 (6) 49 (4)
Operation year 2006-2017 2006-2017
Percentage values are in parentheses (%).
SD, standard deviation.
Fig. 2. Implant survival for the constrained acetabular device and the reference groups
with revision for any reason as the endpoint, using patient death as competing risk.
The 95% CI levels shown around the curves in blue (the reference group) and red (the
constrained acetabular device group). CI, conﬁdence interval; THA, total hip arthro-
plasty; CIF, cumulative incidence function.
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head mold. The reference group consisted of conventional THAs
with 36-mm femoral head size operated during the same time
period from 2006 to 2017. The groups were matched by age group
(<49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80þ years), sex, and
diagnosis (primary osteoarthritis, rheumatoid arthritis, other) in a
1:3 ratio, making a total of 1118 THAs in the reference group
(Table 1). The most common cup models used in the reference
group were Continuum (Zimmer Biomet, Warsaw, IN), Pinnacle
(DePuy,Warsaw, IN), Trident (Stryker, Mahwah, NJ), Exeter (Stryker,
Mahwah, NJ), and Lubinus (Waldemar Link, Hamburg, Germany).Statistics
Implant survival for the constrained acetabular device and
reference groups was calculated from the corresponding cumula-
tive incidence function adjusted for patient death as a competing
event for revision for any reason and revision for any aseptic reason
as the endpoints. Death of the patient and revision are competing
risks in registry studies. Mortality in the constrained acetabular
device group as a whole was 51.7%, and in the control group, 16.3%.
Therefore, we used competing risk survivorship analysis instead of
Kaplan-Meier survivorship. In a Cox regression model, implant
revision hazard ratios (HR) with 95% conﬁdence intervals for any
reason for revision were assessed. Implant revision HRs were also
assessed separately for revisions performed due to dislocation and
for revisions for infection.
Including stem ﬁxation in the Coxmodel as a confounding factor
did not change the results, and as stem ﬁxation data were missing
from 60 operations in the constrained acetabular device group (16%
of all hips in the constrained device group), we decided to exclude it
from the model.
Revisions were linked to the primary operation through a per-
sonal identiﬁcation number. The survival endpoint was deﬁned as
revision when either one of the components or the entire implant
was removed or exchanged, including isolated liner exchanges.
Patients who died during the follow-up period (until December 31,
2017) were censored at that point. Mean follow-up time was 3.3(0-12.4) years for the constrained acetabular device group and 3.8
(0-12.0) years for the reference group.
The proportional hazards assumption of the Cox models was
checked by inspecting the corresponding log-log graphs. For Cox
analyses comparing the constrained device group with the refer-
ence group, we divided the total follow-up time into three periods
(1 to 1.5 years, 1.5 to 3 years, and the 4th year onwards), as the
proportional hazards assumption was not fulﬁlled for the total
follow-up.
Inclusion of bilateral cases in a survival analysis violates the
basic assumption that all cases are independent. However, several
reports have shown that the effect of including bilateral cases in
studies of hip and knee implant survival is negligible [13,14].
Therefore, in this study, we included seven patients with a primary
constrained acetabular device THA in both hips (14 hips alto-
gether), 43 patients with a conventional THA in both hips (86 hips
altogether), and one patient with a constrained device THA in one
hip and conventional THA in the other.
The Wald test was used to test the estimated HRs. Differences
between the groups were considered statistically signiﬁcant if the P
values were <0.05 in a two-tailed test.
Results
Revision for Any Reason
The 8-year survivorship of the constrained acetabular device group
was 94% (conﬁdence interval [CI]: 91-96) and that of the reference
group was 93% (CI: 89-97) (Fig. 2). Overall, there were 21 revisions in
the constrained acetabular device group and 49 in the reference
group. Reasons for revisions are presented in Table 2. During the ﬁrst
1.5 years, the constrained acetabular device group had a similar risk of
revision (HR: 0.92 [CI: 0.48-1.75], P ¼ .8) to the reference group. From
1.5 to 3 years, the constrained acetabular device group had an
increased risk of revision (HR: 6.35 [CI: 1.86-21.7], P ¼ .003) over the
reference group. From the fourth year onwards, the constrained
acetabular device group had a similar risk of revision (HR: 2.02 [CI:
0.33-12.44], P ¼ .4) to the reference group (Table 3).
Revisions due to Dislocation
The constrained acetabular device group had a similar risk of
revision due to dislocation (HR: 0.27 [CI: 0.03-2.05], P ¼ .2)
Table 2
Reason for Revisions.
Reason for Revision Constrained
Acetabular Device
Reference
Aseptic loosening (femur and acetabulum) 0 (0) 2 (4)
Aseptic loosening (acetabulum) 2 (10) 3 (6)
Aseptic loosening (femur) 1 (5) 3 (6)
Infection 10 (48) 11 (22)
Dislocation 1 (5) 12 (24)
Component malposition 1 (5) 2 (4)
Periprosthetic fracture 3 (14) 8 (16)
Other reason 2 (10) 2 (4)
Missing data 1 (5) 6 (12)
Total 21 (100) 49 (100)
Fig. 3. Implant survival for the constrained acetabular device and the reference groups
with revision for any mechanical reason as the endpoint (revisions for infection
excluded), using patient death as competing risk. The 95% CI levels are presented
around the curves in blue (the reference group) and red (the constrained acetabular
device group).
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dislocation in the constrained acetabular device group, and there
were 12 in the reference group.
Revisions due to Any Aseptic Reason (Infections Excluded)
The 8-year survivorship of the constrained acetabular device
group was 97% (CI: 95-99) and that of the reference group was 94%
(CI: 90-98) with any aseptic revision as the endpoint (Fig. 3).
Revisions due to Infection
There were 10 revisions due to infection in the constrained
acetabular device group and 11 in the reference group. The con-
strained acetabular device group had an increased risk of revision
due to infection (HR: 2.99 [CI: 1.27-7.04], P ¼ .01) compared with
the reference group. However, the mortality was signiﬁcantly
higher in the constrained acetabular device group, which indicates
that this study group is more fragile than the control group.
Discussion
We found that the 8-year survivorship of the constrained
acetabular device group was equal to that of the reference group
revision for any reason as the endpoint. There was only one dislo-
cation revision in the constrained acetabular device group
compared with 12 in the matched reference group, although the
difference between the groups was not statistically signiﬁcant.
There was no difference in the overall revision risk between the
constrained acetabular device group and the reference group dur-
ing the ﬁrst 1.5 years, when most of the revisions occurred. To our
knowledge, this is the ﬁrst published prospective, register-based
cohort study assessing the use of a constrained acetabular device
in primary THA.Table 3
HR for the Constrained Acetabular Device and Reference Groups With Revision for
Any Reason as the Endpoint.
Group HR 95% CI P Value
All revisions from 0 to 1.5 y
Constrained acetabular device group
(vs reference group)
0.92 0.48 1.75 .8
All revisions from 1.5 to 3 y
Constrained acetabular device group
(vs reference group)
6.35 1.86 21.70 .003
All revisions from fourth year onwards
Constrained acetabular device group
(vs reference group)
2.02 0.33 12.44 .4
Follow-up time has been divided into three parts (0 to 1.5 year, 1.5 to 3 years, and
from the fourth year onwards) because the proportional hazards assumption of the
Cox model was not fulﬁlled.
HR, hazards ratio; CI, conﬁdence interval.The studied constrained acetabular device was ﬁrst introduced
in Finland in 2006. Since then, this device has shown reasonable
results especially in hip revision arthroplasty and is currently used
worldwide [15e18]. However, peer-reviewed long-term research
reports of the device are still scarce. Recently, in addition to their
use in revision arthroplasty, routine primary THA implant of con-
strained acetabular devices in high-risk patients has also been on
the rise, based on only moderate evidence. In a retrospective study
of 105 consecutive surgical procedures, with the same constrained
acetabular device we studied, from 2007 to 2014 and for a mean
follow-up time of 2.5 years, mechanical failure of the device was
rare (5.7%) [9]. In that study, none of the 11 primary THAs where a
constrained acetabular device was used to prevent dislocation
failed. Failure rates when the constrained acetabular device was
used in revision for dislocation or revision for another reason were
4.8% and 7.7%, respectively. Berend et al. [19] reviewed the out-
comes of 81 consecutive constrained acetabular device compo-
nents of which nine were primary THAs. A constrained acetabular
device was used in 12 hips to address recurrent instability or
complications with a previous constrained device. There was only
one dislocation during the follow-up time, occurring 6months after
insertion of the constrained acetabular device component in a pa-
tient undergoing revision THA. The number of primary THAs has
been low in these earlier single-center studies. Nonetheless, the
results of our present study based on high-quality national register
data are in line with these previous ﬁndings that the constrained
acetabular device works well in preventing revision operations in
high-risk patients undergoing primary THA.
We found no difference in overall revision rate between the
constrained acetabular device group and the reference group dur-
ing the ﬁrst 1.5 years of follow-up, whenmost (77%) of the revisions
occurred. From 1.5 to 3 years postoperatively, the adjusted revision
risk of the constrained acetabular device group was higher than
that in the reference group; the difference is probably attributable
to the overall low number of revisions during this timedonly 11
out of all 70. From the fourth year onwards, the revision risk
returned to being similar between the study groups.
There was only one revision for dislocation in the constrained
acetabular device group compared with 12 in the matched refer-
ence group in the present study. In general, constrained acetabular
devices are used for patients with high risk of instability. This in-
dicates that a constrained acetabular device may help to lower the
dislocation revision rate compared with conventional primary THA
M. Karvonen et al. / The Journal of Arthroplasty 35 (2020) 219e223 223in patients at high dislocation risk, even though the difference in
dislocation risk between the study groups was not statistically
signiﬁcant.
There was no difference in the 8-year survivorship between the
two groups after excluding infections as the cause of revision. It has
been stated previously that constrained implants may have an
increased prevalence of impingement of the femoral neck on the
cup, leading to liner damage, locking mechanism failure, disloca-
tion, and loosening [10]. We did not ﬁnd any evidence to support
this assumption. Overall, there were only two revisions for aseptic
loosening of the cup in the constrained acetabular device group
compared with ﬁve in the reference group, and the difference was
not statistically signiﬁcant. Patients in the constrained acetabular
device group were frailer than those in the reference group, even
after matching, which is indicated by the high mortality rate (51.5%
vs 16.3%, respectively). Therefore, one should be cautious in
extrapolating our results to younger patients with a longer life
expectancy. However, in general, these devices are not routinely
used in younger and ﬁtter patients.
Interestingly, the constrained acetabular device group had a
statistically signiﬁcantly increased risk of revision because of
infection comparedwith the reference group (HR: 2.99, P¼ .01).We
theorized that this is more likely to be associated with patient se-
lection than with the implant itself, as constrained acetabular de-
vices are used in frailer patients at increased risk of infection.
Unfortunately, we were not able to adjust the data for comorbid-
ities, which are a well-known risk factor for deep infection [20].
Furthermore, the current approach of including bilateral hip cases
may in theory be biased when studying the rate of revision due to
infection as there is potentially higher risk of contralateral THA
developing periprosthetic joint infection when a patient has a
current THA with conﬁrmed periprosthetic joint infection and
potentially septic. However, we think this bias is of theoretical
importance only.
We acknowledge that our study has several limitations. As with
any register research, we were limited to the data the register
provides. There are several factors we did not have access to that
might have an effect on instability, such as alcoholism, spinal
fusion, abductor deﬁciency, polio, bodymass index, or dementia. As
mentioned earlier, patient selection in regard to constrained
acetabular devices tends to lean on more fragile patients. By
matching the study groups, wewere able at least somewhat reduce
these confounding factors. Also, we were not able to assess the
patients’ radiographs. Furthermore, we were only able to use
revision as the outcome. Some of the patients might have suffered
pain or had other problems with their implant without having a
revision, for example, due to poor general health. Moreover, our
results are based on a single constrained acetabular device and are
not generalizable to other constrained designs. A strength of our
study is the independent population-based cohort design with
prospective collection of data and large sample size. The FAR has a
high degree of completeness and coverage and thereby provides a
representative study population.
Conclusion
In summary, we found that the 8-year survivorship for the
constrained acetabular device group was equal to that of the con-
ventional THA group with revision for any reason as the endpoint.There was only one dislocation revision in the constrained
acetabular device group compared with 12 dislocation revisions in
the matched reference group, although the difference was not
statistically signiﬁcant. Our current national register-based results
indicate that the constrained acetabular device works well in pa-
tients undergoing primary THA with high instability risk.Acknowledgments
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